{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2021)
Source URL:
First approved in 2018
Source:
21 CFR 333E
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 347
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Bei Ling Tong Bao Er Zheng Yuan Antibacterial Creams by Jilin Mancaotang Health Management Group Co Ltd
(2018)
Source URL:
First approved in 2018
Source:
Bei Ling Tong Bao Er Zheng Yuan Antibacterial Creams by Jilin Mancaotang Health Management Group Co Ltd
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Psoralen, the active ingredient of Fructus Psoraleae (FP) the dried ripe fruit of Psoralea corylifolia L., which is used in Chinese herbal medicine. Psoralen promotes chondrocyte proliferation by activating the Wnt/β-catenin signaling pathway and can play an important role in the treatment of osteoarthritis. Besides, this compound stimulates osteoblast proliferation through the activation of NF-κB and MAPK signaling and may be a viable therapeutic agent in the treatment of osteoporosis.
Status:
Possibly Marketed Outside US
Source:
NADA141508
(2018)
Source URL:
First approved in 2018
Source:
NADA141508
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Lubabegron was initially studied in the Eli Lilly’s lab for potential applications in human health. The drug is a beta-adrenergic agonist that has the effect of increasing the breakdown of fats and increasing energy expenditure in cells. Lubabegron is the first animal drug that was approved to reduce ammonia gas emissions from an animal or its waste. These ammonia gasses can come from many sources and can affect the health of people, animals and the environment.
Status:
Possibly Marketed Outside US
Source:
M019
(2020)
Source URL:
First approved in 2018
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
First approved in 2018
Source:
21 CFR 343
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ethenzamide is an anti-inflammatory agent that was used for the treatment of common cold in Japan (in combinations with other NSAIDs).
Status:
Possibly Marketed Outside US
Source:
M020
(2018)
Source URL:
First approved in 2018
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)